{ "items" : [
    { "id" : "http://dbpedia.org/resource/Zanamivir"
      "properties" : {
        "http://www.w3.org/2000/01/rdf-schema#comment" : [ "Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.  Zanamivir was the first neuraminidase inhibitor commercially developed." ] ,
        "http://xmlns.com/foaf/0.1/depiction" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Zanamivir_structure.svg" ] ,
        "http://dbpedia.org/ontology/atcPrefix" : [ "J05" ] ,
        "http://dbpedia.org/ontology/atcSuffix" : [ "AH01" ] ,
        "http://dbpedia.org/ontology/bioavailability" : [ 2 ] ,
        "http://dbpedia.org/ontology/casNumber" : [ "139110-80-8" ] ,
        "http://dbpedia.org/ontology/chEBI" : [ "50663" ] ,
        "http://dbpedia.org/ontology/drugbank" : [ "DB00558" ] ,
        "http://dbpedia.org/ontology/fdaUniiCode" : [ "L6O3XI777I" ] ,
        "http://dbpedia.org/ontology/iupacName" : [ "(2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid" ] ,
        "http://dbpedia.org/ontology/pubchem" : [ "60855" ] ,
        "http://dbpedia.org/ontology/thumbnail" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Zanamivir_structure.svg?width=300"] } } }
